OBJECTIVES: To evaluate the efficacy and treatment-related toxicity of accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer (LRIRC). METHODS: 72 patients with LRIRC who underwent the treatment were studied. Three-dimensional conformal accelerated hyperfractionation radiotherapy (3D-CAHRT) was performed and the dose was delivered with a schedule of 1.2 Gy twice daily, with an interval of at least 6 h between fractions, 5 days a week. Concurrent capecitabine chemotherapy was administered twice daily. After 36 Gy in 30 fractions over 3 weeks, patients were evaluated to define the resectability of the disease. If resection was not feasible irradiation was resumed until the total dose administered to the tumour reached 51.6-56.4 Gy. RESULTS: Two patients temporarily interrupted concurrent chemoradiation because of Grade IV diarrhoea. The remaining 70 patients completed the planned concurrent chemoradiation. In all patients, the complete response rate was 8.3% and the partial response rate was 51.4%. The overall response rate was 59.7% and clinical benefit rate was 93.1%. Symptomatic responses proved to be obvious and tumour resection was performed in 18 patients. The overall median survival time and median progression-free survival time were 32 and 17 months, respectively. 3 year overall survival and progression-free survival were 45.12% and 31.19%, respectively. Severely acute toxicities included Grade III-IV diarrhoea and granulocytopenia with 9.7% and 8.3% incidence respectively. Small bowel obstruction was severely late toxicity, and the incidence was 1.4%. CONCLUSION: Three-dimensional conformal accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy might be an effective and well-tolerated regimen for patients with LRIRC.
OBJECTIVES: To evaluate the efficacy and treatment-related toxicity of accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer (LRIRC). METHODS: 72 patients with LRIRC who underwent the treatment were studied. Three-dimensional conformal accelerated hyperfractionation radiotherapy (3D-CAHRT) was performed and the dose was delivered with a schedule of 1.2 Gy twice daily, with an interval of at least 6 h between fractions, 5 days a week. Concurrent capecitabine chemotherapy was administered twice daily. After 36 Gy in 30 fractions over 3 weeks, patients were evaluated to define the resectability of the disease. If resection was not feasible irradiation was resumed until the total dose administered to the tumour reached 51.6-56.4 Gy. RESULTS: Two patients temporarily interrupted concurrent chemoradiation because of Grade IV diarrhoea. The remaining 70 patients completed the planned concurrent chemoradiation. In all patients, the complete response rate was 8.3% and the partial response rate was 51.4%. The overall response rate was 59.7% and clinical benefit rate was 93.1%. Symptomatic responses proved to be obvious and tumour resection was performed in 18 patients. The overall median survival time and median progression-free survival time were 32 and 17 months, respectively. 3 year overall survival and progression-free survival were 45.12% and 31.19%, respectively. Severely acute toxicities included Grade III-IV diarrhoea and granulocytopenia with 9.7% and 8.3% incidence respectively. Small bowel obstruction was severely late toxicity, and the incidence was 1.4%. CONCLUSION: Three-dimensional conformal accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy might be an effective and well-tolerated regimen for patients with LRIRC.
Authors: Bryan J Wells; Peter Stotland; Michael A Ko; Wigdan Al-Sukhni; Jay Wunder; Peter Ferguson; Joan Lipa; Linda Last; Andrew J Smith; Carol J Swallow Journal: Ann Surg Oncol Date: 2006-10-25 Impact factor: 5.344
Authors: Miranda Kusters; Raphaëla C Dresen; Hendrik Martijn; Grard A Nieuwenhuijzen; Cornelis J H van de Velde; Hetty A van den Berg; Regina G H Beets-Tan; Harm J T Rutten Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-22 Impact factor: 7.038
Authors: Vincenzo Valentini; Alessio G Morganti; M Antonietta Gambacorta; Mohammed Mohiuddin; G Battista Doglietto; Claudio Coco; Antonino De Paoli; Carlo Rossi; Annamaria Di Russo; Francesca Valvo; Giampaolo Bolzicco; Maurizio Dalla Palma Journal: Int J Radiat Oncol Biol Phys Date: 2006-01-18 Impact factor: 7.038
Authors: Tse-Kuan Yu; Priya R Bhosale; Christopher H Crane; Revathy B Iyer; John M Skibber; Miguel A Rodriguez-Bigas; Barry W Feig; George J Chang; Cathy Eng; Robert A Wolff; Nora A Janjan; Marc E Delclos; Sunil Krishnan; Prajnan Das Journal: Int J Radiat Oncol Biol Phys Date: 2008-01-22 Impact factor: 7.038
Authors: Ari Ballonoff; Brian Kavanagh; Martin McCarter; Madeleine Kane; Nathan Pearlman; Russell Nash; Raj J Shah; David Raben; Tracey E Schefter Journal: Am J Clin Oncol Date: 2008-06 Impact factor: 2.339
Authors: Raphaëla C Dresen; Marleen J Gosens; Hendrik Martijn; Grard A Nieuwenhuijzen; Geert-Jan Creemers; Alette W Daniels-Gooszen; Adriaan J van den Brule; Hetty A van den Berg; Harm J Rutten Journal: Ann Surg Oncol Date: 2008-04-04 Impact factor: 5.344
Authors: Amelia Barcellini; Viviana Vitolo; Lorenzo Cobianchi; Andrea Peloso; Alessandro Vanoli; Alfredo Mirandola; Angelica Facoetti; Maria Rosaria Fiore; Alberto Iannalfi; Barbara Vischioni; Francesco Cuccia; Sara Ronchi; Maria Bonora; Giulia Riva; Rachele Petrucci; Emma D'Ippolito; Francesca Dal Mas; Lorenzo Preda; Francesca Valvo Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155
Authors: Amar U Kishan; Justin C Voog; Jonathan Wiseman; Ryan R Cook; Marek Ancukiewicz; Percy Lee; David P Ryan; Jeffrey W Clark; David L Berger; James C Cusack; Jennifer Y Wo; Theodore S Hong Journal: Br J Radiol Date: 2017-06-14 Impact factor: 3.039
Authors: Andrew R Barsky; Vishruth K Reddy; John P Plastaras; Edgar Ben-Josef; James M Metz; Andrzej P Wojcieszynski Journal: J Gastrointest Oncol Date: 2020-02